Tetrathiomolybdate

DRUG9 trials

Conditions

Breast CancerCarcinoma, HepatocellularColorectal CarcinomaIdiopathic Pulmonary FibrosisNon-Small Cell Lung CancerPrimary Biliary CirrhosisProstate CancerResidual Disease

Phase 1

Safety Study of Tetrathiomolybdate in Patients With Idiopathic Pulmonary Fibrosis

CompletedNCT00189176

University of MichiganIdiopathic Pulmonary Fibrosis

Start: 2003-03-31End: 2006-05-31Updated: 2013-02-06

Phase I Study of Tetrathiomolybdate in Combination With Carboplatin/Pemetrexed in Metastatic Non-small Cell Lung Cancer

CompletedNCT01837329

University of RochesterNon-Small Cell Lung Cancer

Start: 2013-11-30End: 2019-01-11Updated: 2019-07-19

A Study of Tetrathiomolybdate (TM) Plus Capecitabine

RecruitingNCT06134375

Dartmouth-Hitchcock Medical CenterResidual Disease, Triple Negative Breast Cancer

Start: 2024-11-26End: 2036-06-26Target: 204Updated: 2026-04-20

Phase 2

Treatment of Hepatocellular Carcinoma With Tetrathiomolybdate

CompletedNCT00006332

National Center for Research Resources (NCRR)Carcinoma, Hepatocellular

Updated: 2005-06-24

Tetrathiomolybdate in Hormone Refractory Prostate Cancer

CompletedNCT00150995

University of Michigan Rogel Cancer CenterProstate Cancer

Start: 2001-05-31End: 2006-04-30Updated: 2015-01-21

Irinotecan, 5-Fluorouracil, and Leucovorin in Colorectal Carcinoma

CompletedNCT00176774

University of Michigan Rogel Cancer CenterColorectal Carcinoma

Start: 2001-02-28End: 2004-04-30Updated: 2012-02-07

Phase II Study of Tetrathiomolybdate (TM) in Patients With Breast Cancer

TerminatedNCT00195091

Memorial Sloan Kettering Cancer CenterBreast Cancer

Start: 2003-12-31End: 2023-03-02Updated: 2025-05-16

Phase 3

Study of Tetrathiomolybdate in Patients With Wilson Disease

CompletedNCT00004339

National Center for Research Resources (NCRR)Wilson Disease

Start: 1994-01-31Target: 90Updated: 2006-05-09

Study Comparing Tetrathiomolybdate vs Standard Treatment in Primary Biliary Cirrhosis

CompletedNCT00805805

George BrewerPrimary Biliary Cirrhosis

Start: 2006-04-30End: 2008-12-31Updated: 2017-05-23

Related Papers

PS5-09-26: Digital health adherence companion study for tetrathiomolybdate (TM) plus capecitabine in triple-negative breast cancer

Clinical Cancer Research2026-02-17

Abstract PS5-07-23: Novel Targeting of the Microenvironment to Decrease Metastatic Recurrence of High-Risk TNBC: A Randomized Phase 2 Study of Tetrathiomolybdate (TM), an oral copper depletion agent plus capecitabine +/- pembrolizumab in patients with breast cancer at high risk of recurrence (NCT06134375)